TP5. TP005 INTERSTITIAL LUNG DISEASE PATHOGENESIS

Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) for Idiopathic Pulmonary Fibrosis: Study Design of STARSCAPE, A Phase III Randomized Double Blind Placebo Controlled Trial

Pub Date : 1900-01-01 DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1330 L. Richeldi, K. Anstrom, J. Behr, T. Corte, V. Cottin, G. Jenkins, N. Kamath, Y. Inoue, S. Nathan, G. Raghu, J. Randhawa, S. Walsh, F. J. Martínez

Interleukin-23 Amplifies EMT on Mechanically Conditioned Type I Alveolar Epithelial Cells Through mTORC1/S6 Pathway

Pub Date : 1900-01-01 DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1336 C. Zhang, S. Wang, E. Matteson, R. Vassallo

Impact of Forced Vital Capacity Decline on Hospitalization Events in Systemic Sclerosis-Associated Interstitial Lung Disease: A Joint Model Analysis Using Data from the SENSCIS® Trial

Pub Date : 1900-01-01 DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1328 M. Kreuter, F. del Galdo, C. Miede, D. Khanna, W. Wuyts, L. Hummers, M. Alves, N. Schoof, C. Stock, Y. Allanore